Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage
after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy
(PDRP).